Matches in SemOpenAlex for { <https://semopenalex.org/work/W2478525412> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2478525412 endingPage "100" @default.
- W2478525412 startingPage "100" @default.
- W2478525412 abstract "Metastatic melanoma is a very common disease with an increasing incidence worldwide and is notoriously difficult to treat. The long-established treatments including dacarbazine and interleukin-2 have shown limited response rates and are associated with significant toxicities. More recently, treatments have been developed that decrease inhibition of T-cell action against melanomas. Among these, ipilimumab was recently approved for use in metastatic melanoma and has shown improved overall survival (OS) and progression-free survival rates (PFS). Another such treatment currently in development is the monoclonal antibody, anti-PD-1. This blocks PD-1 inhibition of T-cells and has shown promising response rates in early clinical trials. Another treatment approach is to use targeted therapies in patients with mutations in BRAF or CKIT signaling pathways and it is vital that the mutational status of these genes be determined in patients with metastatic melanoma to best determine effective therapeutic options. Vemurafenib was recently approved for metastatic melanoma and targets the BRAF V600E mutation which occurrs in about 50 % of cutaneous melanomas. Recent results from the ongoing Phase III BRIM-3 study comparing vemurafenib with dacarbazine showed that median 12-month OS rates and the risk of death were reduced with vemurafenib. Other BRAF inhibitors such as dabrafenib and MEK inhibitors such as trametinib are also in development. New treatments in ongoing clinical trials coupled with an improved biologic understanding are likely to improve responses and outcomes for patients with metastatic melanoma." @default.
- W2478525412 created "2016-08-23" @default.
- W2478525412 creator A5002655892 @default.
- W2478525412 creator A5029017725 @default.
- W2478525412 creator A5035427219 @default.
- W2478525412 date "2012-01-01" @default.
- W2478525412 modified "2023-09-25" @default.
- W2478525412 title "Time for a New Paradigm in the Treatment of Metastatic Melanoma" @default.
- W2478525412 doi "https://doi.org/10.17925/ohr.2012.08.2.100" @default.
- W2478525412 hasPublicationYear "2012" @default.
- W2478525412 type Work @default.
- W2478525412 sameAs 2478525412 @default.
- W2478525412 citedByCount "0" @default.
- W2478525412 crossrefType "journal-article" @default.
- W2478525412 hasAuthorship W2478525412A5002655892 @default.
- W2478525412 hasAuthorship W2478525412A5029017725 @default.
- W2478525412 hasAuthorship W2478525412A5035427219 @default.
- W2478525412 hasBestOaLocation W24785254121 @default.
- W2478525412 hasConcept C121608353 @default.
- W2478525412 hasConcept C126322002 @default.
- W2478525412 hasConcept C143998085 @default.
- W2478525412 hasConcept C184235292 @default.
- W2478525412 hasConcept C2776131300 @default.
- W2478525412 hasConcept C2777658100 @default.
- W2478525412 hasConcept C2777701055 @default.
- W2478525412 hasConcept C2778472372 @default.
- W2478525412 hasConcept C2778830669 @default.
- W2478525412 hasConcept C2780964509 @default.
- W2478525412 hasConcept C2781433595 @default.
- W2478525412 hasConcept C2994587330 @default.
- W2478525412 hasConcept C502942594 @default.
- W2478525412 hasConcept C535046627 @default.
- W2478525412 hasConcept C57074206 @default.
- W2478525412 hasConcept C71924100 @default.
- W2478525412 hasConcept C86803240 @default.
- W2478525412 hasConcept C95444343 @default.
- W2478525412 hasConceptScore W2478525412C121608353 @default.
- W2478525412 hasConceptScore W2478525412C126322002 @default.
- W2478525412 hasConceptScore W2478525412C143998085 @default.
- W2478525412 hasConceptScore W2478525412C184235292 @default.
- W2478525412 hasConceptScore W2478525412C2776131300 @default.
- W2478525412 hasConceptScore W2478525412C2777658100 @default.
- W2478525412 hasConceptScore W2478525412C2777701055 @default.
- W2478525412 hasConceptScore W2478525412C2778472372 @default.
- W2478525412 hasConceptScore W2478525412C2778830669 @default.
- W2478525412 hasConceptScore W2478525412C2780964509 @default.
- W2478525412 hasConceptScore W2478525412C2781433595 @default.
- W2478525412 hasConceptScore W2478525412C2994587330 @default.
- W2478525412 hasConceptScore W2478525412C502942594 @default.
- W2478525412 hasConceptScore W2478525412C535046627 @default.
- W2478525412 hasConceptScore W2478525412C57074206 @default.
- W2478525412 hasConceptScore W2478525412C71924100 @default.
- W2478525412 hasConceptScore W2478525412C86803240 @default.
- W2478525412 hasConceptScore W2478525412C95444343 @default.
- W2478525412 hasIssue "02" @default.
- W2478525412 hasLocation W24785254121 @default.
- W2478525412 hasOpenAccess W2478525412 @default.
- W2478525412 hasPrimaryLocation W24785254121 @default.
- W2478525412 hasRelatedWork W112030529 @default.
- W2478525412 hasRelatedWork W1996920559 @default.
- W2478525412 hasRelatedWork W1998772295 @default.
- W2478525412 hasRelatedWork W2025130458 @default.
- W2478525412 hasRelatedWork W2026196315 @default.
- W2478525412 hasRelatedWork W2051094475 @default.
- W2478525412 hasRelatedWork W2137553818 @default.
- W2478525412 hasRelatedWork W2605233023 @default.
- W2478525412 hasRelatedWork W2914108875 @default.
- W2478525412 hasRelatedWork W4246006194 @default.
- W2478525412 hasVolume "08" @default.
- W2478525412 isParatext "false" @default.
- W2478525412 isRetracted "false" @default.
- W2478525412 magId "2478525412" @default.
- W2478525412 workType "article" @default.